Ticker: XGN

Exagen Inc. (NASDAQ: XGN) - Q2 2025 Financial Overview Exagen Inc. continues its focus on autoimmune diagnostic testing, reporting notable developments and financial results from its Q2 2025 earnings report. The company aims to improve its offering through innovations while navigating financial c...

Exagen Inc. (NASDAQ: XGN) recently released its quarterly financial results for the period ended March 31, 2025. Below is a comprehensive overview of the company's performance, highlighting both the positive and negative aspects of its income statement. Key Financial Metrics: Revenue: $15.5 mill...